Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) have been assigned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $43.00.
BCAX has been the topic of several research reports. Morgan Stanley began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price objective on the stock. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. TD Cowen assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set a “buy” rating for the company. Stifel Nicolaus began coverage on shares of Bicara Therapeutics in a report on Tuesday, October 8th. They issued a “buy” rating and a $47.00 price objective on the stock. Finally, Rodman & Renshaw initiated coverage on shares of Bicara Therapeutics in a report on Tuesday, November 5th. They set a “buy” rating and a $48.00 target price for the company.
Check Out Our Latest Stock Report on Bicara Therapeutics
Institutional Inflows and Outflows
Bicara Therapeutics Stock Performance
Shares of NASDAQ:BCAX opened at $11.92 on Monday. The company has a 50 day moving average price of $17.46. Bicara Therapeutics has a fifty-two week low of $11.51 and a fifty-two week high of $28.09.
Bicara Therapeutics (NASDAQ:BCAX – Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, analysts forecast that Bicara Therapeutics will post -2.59 EPS for the current fiscal year.
Bicara Therapeutics Company Profile
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
See Also
- Five stocks we like better than Bicara Therapeutics
- Most active stocks: Dollar volume vs share volume
- Oracle Announces Game-Changing News for the AI Industry
- There Are Different Types of Stock To Invest In
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- What is a Death Cross in Stocks?
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Bicara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.